SDZ 215918
Latest Information Update: 15 Jun 2001
At a glance
- Originator Novartis
- Class Antiparasitics
- Mechanism of Action P-glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Toxoplasmosis
Most Recent Events
- 15 Jun 2001 No-Development-Reported for Toxoplasmosis in USA (Unknown route)
- 23 Oct 1997 New profile
- 23 Oct 1997 Preclinical development for Toxoplasmosis in USA (Unknown route)